Molecular Partners AG
Molecular Partners AG (SIX: MOLN) is trading at CHF 3.22, about ₹372 at today's CHF/INR rate, as of 25 Sep 2026, 11:30 AM ET, down 5.29% today. Indian residents can buy Molecular Partners from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
CHF 3.22
Today's high
CHF 3.49
52 week low
CHF 2.66
52 week high
CHF 3.96
MOLN opened at CHF 3.38, closed previously at CHF 3.40, and has traded between CHF 2.66 and CHF 3.96 over the past 52 weeks.
About
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Key statistics
Avg. volume
15.44K
Market cap
CHF 120.79M
P/E Ratio
-2.37
Price-to-sales ratio
0.00
Enterprise value
CHF 55.90M
Free cash flow yield
-37.79%
Debt-to-equity ratio
0.05
Return on equity
-67.67%
ROIC
-76.91%
Beta
0.69
Dividend yield
0.00%
Last dividend
CHF 0.00
Financial overview
Revenue
CHF 0.00
Earnings per share
-CHF 1.65
Free cash flow
-CHF 50.24M
Net profit margin
0.00%
Gross margin
0.00%
EBITDA
-CHF 53.26M
Revenue growth
-100.00%
Similar securities
This is not an investment recommendation
How to buy Molecular Partners from India
Indian residents can buy Molecular Partners shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to CHF.
Search for Molecular Partners and place an order
Find Molecular Partners by name or by its ticker, MOLN, and choose an order type. Molecular Partners trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Molecular Partners position in CHF and INR. Molecular Partners pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Molecular Partners from India
Trading and taxes when buying Molecular Partners from India
Trading and limits
- Trading hours
- 9:00 am – 5:30 pm CET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneMolecular Partners does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Molecular Partners stock?
Yes. Molecular Partners (MOLN) has been listed on the SIX Swiss Exchange since 2015, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to CHF. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Molecular Partners share cost in rupees?
One Molecular Partners share is CHF 3.22 — about ₹372 at a CHF/INR rate of 115.66 on 26 Sep 2026. Both the Molecular Partners price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Molecular Partners from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on Molecular Partners shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the CHF/INR rate on the purchase and the sale date, so the rupee move counts alongside the Molecular Partners price. Paasa issues a capital-gains statement for your return.
Does Molecular Partners pay a dividend?
No. Molecular Partners does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Molecular Partners from India?
The SIX Swiss Exchange trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when Switzerland is on standard time. Orders can only execute during that window.
Do I have to declare Molecular Partners shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Molecular Partners holding, its cost and its closing value.
How do I sell Molecular Partners and bring the money back to India?
You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in CHF in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on Molecular Partners?
Yes. Molecular Partners is priced in CHF, so your rupee outcome combines the CHF move with the CHF/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.